Immuron (IMRN) Total Current Liabilities (2015 - 2026)
Immuron (IMRN) posted Total Current Liabilities of $1.8 million for Q3 2026, down 9.19% on a QoQ basis from $2.0 million in Q4 2025, and up 8981.05% year-over-year from $19662.1 in Q3 2025.
Analysis
Immuron (IMRN) Total Current Liabilities (2015 - 2026) Analysis & Trends
Immuron has reported Total Current Liabilities for 12 years, with the latest figure at $1.8 million in Q3 2026.
- On a quarterly basis, Total Current Liabilities rose 8981.05% year-over-year to $1.8 million in Q3 2026; TTM through Aug 2026 was $1.8 million, a 8981.05% increase from a year earlier, with the FY2026 full-year figure at $1.8 million, up 8981.05% from the prior year.
- Total Current Liabilities was $1.8 million for Q3 2026 at Immuron, down from $2.0 million in the prior quarter.
- The five-year high for Total Current Liabilities was $2.0 million in Q4 2025, with the low at $17984.2 in Q3 2024.
- Average Total Current Liabilities over 5 years is $1.2 million, with a median of $1.4 million recorded in 2023.
- The sharpest annual moves came in 2023 and 2026: Total Current Liabilities sank 97.88% in 2023, then soared 8981.05% in 2026.
- Over 5 years, Total Current Liabilities stood at $987488.0 in 2022, then soared by 46.29% to $1.4 million in 2023, then advanced by 22.18% to $1.8 million in 2024, then climbed by 11.4% to $2.0 million in 2025, then retreated by 9.19% to $1.8 million in 2026.
- The last three Total Current Liabilities figures came in at $1.8 million (Q3 2026), $2.0 million (Q4 2025), and $19662.1 (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn | 25.50 Bn |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn | 11.02 Bn |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | 3.94 Bn |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn | 5.53 Bn |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn | 1.58 Bn |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn | 2.53 Bn |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn | 1.51 Bn |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn | 3.92 Bn |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn | 283.60 Mn |
| 10 | Immuron | 10.28 Mn | 1.26 Mn | - | 1.79 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Aug 28, 2026 | 1.79 Mn |
| Dec 31, 2025 | 1.97 Mn |
| Sep 2, 2025 | 19,662.09 |
| Jun 30, 2025 | 1.26 Mn |
| Dec 31, 2024 | 1.77 Mn |
| Sep 9, 2024 | 17,984.24 |
| Jun 30, 2024 | 1.78 Mn |
| Dec 31, 2023 | 1.44 Mn |
| Sep 28, 2023 | 1.45 Mn |
| Aug 30, 2023 | 22,191.39 |
| Jun 30, 2023 | 1.48 Mn |
| Dec 31, 2022 | 987,488.00 |
| Aug 31, 2022 | 1.05 Mn |
| Jun 30, 2022 | 1.08 Mn |
| Dec 31, 2021 | 821,216.68 |
| Sep 30, 2021 | 824,927.77 |
| Jun 30, 2021 | 863,888.67 |
| Dec 31, 2020 | 377,462.76 |
| Sep 1, 2020 | 516,411.00 |
| Jun 30, 2020 | 338,466.42 |